liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial
Lund University Hospital.
Lund University Hospital.
Lund University Hospital.
Linköping University, Department of Clinical and Experimental Medicine, Oncology . Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre of Surgery and Oncology, Department of Oncology UHL.
Show others and affiliations
2009 (English)In: European Journal of Cancer, ISSN 0959-8049, Vol. 45, no 14, 2496-2502 p.Article in journal (Refereed) Published
Abstract [en]

Background: Adjuvant treatment with tamoxifen reduces the risk of contralateral breast cancer in hormone-responsive postmenopausal patients, whereas the effect in premenopausal women has not been fully elucidated. We have therefore studied the effect of tamoxifen on contralateral breast cancer in premenopausal women in a controlled randomised trial. Patients and methods: Premenopausal women (564) with stage II breast cancers were randomised to 2 years of tamoxifen versus control irrespective of oestrogen receptor (ER) and progesterone receptor (PgR) status. The median follow-up for patients not developing a contralateral cancer was 14 years. Results: In the control group 35 women, and in the tamoxifen group 17 women, developed a contralateral breast cancer as a primary event. Tamoxifen significantly reduced the risk of contralateral breast cancer in all women regardless of age (hazard ratio (HR) 0.5, p = 0.02). In subgroup analysis the risk reduction was most pronounced in patients less than40 years of age (HR 0.09, p = 0.02). A risk reduction was also seen in women 40-49 years of age or ≥50 years of age, although in these subgroups this did not reach statistical significance. The reduced risk of contralateral breast cancer was persistent during the whole follow-up time. Conclusion: In this randomised trial, adjuvant treatment using tamoxifen for 2 years reduced the incidence of contralateral breast cancer by 50% in all premenopausal women, and by 90% in women less than40 years of age. The effect of tamoxifen was not significantly dependent on time.

Place, publisher, year, edition, pages
2009. Vol. 45, no 14, 2496-2502 p.
Keyword [en]
Adjuvant tamoxifen; Breast cancer; Contralateral breast cancer; Hormone receptor status; Premenopausal; Randomised controlled trial
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-21241DOI: 10.1016/j.ejca.2009.05.022OAI: oai:DiVA.org:liu-21241DiVA: diva2:240990
Available from: 2009-09-30 Created: 2009-09-30 Last updated: 2009-09-30

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Nordenskjöld, Bo

Search in DiVA

By author/editor
Nordenskjöld, Bo
By organisation
Oncology Faculty of Health SciencesDepartment of Oncology UHL
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 77 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf